CVS Health Co. (NYSE:CVS) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lessened its stake in shares of CVS Health Co. (NYSE:CVS) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,673 shares of the pharmacy operator’s stock after selling 95,147 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in CVS Health were worth $614,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Coppell Advisory Solutions LLC lifted its holdings in shares of CVS Health by 17.3% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator’s stock valued at $56,000 after purchasing an additional 189 shares during the last quarter. EagleClaw Capital Managment LLC lifted its position in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock worth $275,000 after acquiring an additional 200 shares during the period. Manchester Capital Management LLC lifted its position in CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock worth $200,000 after acquiring an additional 204 shares during the period. Angeles Investment Advisors LLC increased its holdings in shares of CVS Health by 3.7% in the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 204 shares during the period. Finally, Rogco LP raised its stake in shares of CVS Health by 3.2% during the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock worth $303,000 after purchasing an additional 210 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 1.3 %

CVS Health stock opened at $66.98 on Friday. The stock has a market cap of $84.45 billion, a PE ratio of 18.30, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average price of $66.96 and a 200 day moving average price of $59.03. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same quarter in the previous year, the business posted $1.31 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. Equities research analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.97%. The ex-dividend date was Tuesday, April 22nd. CVS Health’s payout ratio is 63.48%.

Insider Buying and Selling at CVS Health

In related news, Director Michael F. Mahoney purchased 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 1.22% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CVS. Truist Financial upped their price objective on shares of CVS Health from $76.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, April 11th. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an “overweight” rating in a research report on Tuesday, February 18th. Cantor Fitzgerald upgraded CVS Health from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 12th. UBS Group lifted their price target on CVS Health from $67.00 to $71.00 and gave the company a “neutral” rating in a research note on Friday, May 2nd. Finally, StockNews.com upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $74.81.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.